Corvus Pharmaceuticals Inc. (C17)
XDUS 
Summary
C17 Chart
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2026 Earnings Call Transcript
Corvus Pharmaceuticals Q2 Earnings Call Highlights
Corvus Pharmaceuticals NASDAQ: CRVS reported a wider second-quarter loss as it increased spending on clinical development of soquelitinib, its selective ITK inhibitor, while outlining expected milestones across programs in peripheral T-cell lymphoma, atopic dermatitis, hidradenitis suppurativa and asthma.
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Corvus Pharmaceuticals Inc. (C17) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Corvus Pharmaceuticals Inc. ever had a stock split?
Corvus Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Richard A. Miller CEO | XDUS Exchange | US2210151005 ISIN |
| US Country | 37 Employees | - Last Dividend | - Last Split | 23 Mar 2016 IPO Date |
Overview
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of pioneering immuno-oncology therapies. With a focus on leveraging the body's immune system to battle cancer, Corvus is at the forefront of designing treatments that target the most challenging cancers. The company was founded in 2014 and is headquartered in Burlingame, California. It characterizes itself through its robust pipeline of therapeutic candidates aimed at treating a variety of cancers by manipulating different aspects of the immune system. Their strategic partnership with Angel Pharmaceuticals underscores their commitment to advancing their research and bringing innovative cancer therapies to market.
Products and Services
- Mupadolimab (CPI-006)
- CPI-818
- Ciforadenant (CPI-444)
- Preclinical Stage Products
This leading product candidate is an anti-CD73 monoclonal antibody currently in a Phase I/Ib clinical trial. It is being investigated for its potential in treating non-small cell lung cancer and head and neck cancers by targeting a pathway believed to suppress the immune system's ability to fight tumors.
CPI-818 is a covalent inhibitor of ITK, and it's in the Phase I/Ib clinical trial stage targeting the treatment of patients with various malignant T-cell lymphomas. The drug is designed to inhibit the proliferation of certain malignant T-cells, offering a novel approach to tackling these types of cancers.
This oral, small molecule antagonist of the A2A receptor is in a Phase II clinical trial targeting patients with advanced or refractory renal cell cancer. By blocking the A2A receptor, Ciforadenant aims to rejuvenate the immune system's ability to attack cancer cells, offering a promising avenue for patients with limited options.
In addition to its clinical-stage products, Corvus Pharmaceuticals is developing several preclinical stage products, including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. These early-stage products represent the company's ongoing commitment to expanding its portfolio and exploring new pathways for cancer treatment.
